Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 112
Filter
Add more filters










Publication year range
1.
Mol Vis ; 17: 1877-90, 2011.
Article in English | MEDLINE | ID: mdl-21850162

ABSTRACT

PURPOSE: The outflow facility for aqueous humor across the trabecular meshwork (TM) is enhanced by agents that oppose the actomyosin contraction of its resident cells. Phosphorylation of MYPT1 (myosin light chain [MLC] phosphatase complex of Type 1) at Thr853 and Thr696 inhibits dephosphorylation of MLC, leading to an increase in actomyosin contraction. In this study, we examined the effects of Rho kinase (ROCK) inhibitors on the relative dephosphorylation of the two sites of MYPT1 using human TM cells (GTM3). METHODS: Dephosphorylation of MYPT1 at Thr853 and Thr696 was determined by western blot analysis following exposure to selective inhibitors of ROCK, namely Y-27632 and Y-39983. Consequent dephosphorylation of MLC and decreases in actomyosin contraction were assessed by western blot analysis and collagen gel contraction assay, respectively. Changes in the cell-matrix adhesion were measured in real time by electric cell-substrate impedance sensing and also assessed by staining for paxillin, vinculin, and focal adhesion kinase (FAK). RESULTS: Both ROCK inhibitors produced a concentration-dependent dephosphorylation at Thr853 and Thr696 of MYPT1 in adherent GTM3 cells. IC50 values for Y-39983 were 15 nM and 177 nM for dephosphorylation at Thr853 and Thr696, respectively. Corresponding values for Y-27632 were 658 nM and 2270 nM. Analysis of the same samples showed a decrease in MLC phosphorylation with IC50 values of 14 nM and 1065 nM for Y-39983 and Y-27632, respectively. Consistent with these changes, both inhibitors opposed contraction of collagen gels induced by TM cells. Exposure of cells to the inhibitors led to a decrease in the electrical cell-substrate resistance, with the effect of Y-39983 being more pronounced than Y-27632. Treatment with these ROCK inhibitors also showed a loss of stress fibers and a concomitant decrease in tyrosine phosphorylation of paxillin and FAK. CONCLUSIONS: Y-39983 and Y-27632 oppose ROCK-dependent phosphorylation of MYPT1 predominantly at Thr853 with a corresponding decrease in MLC phosphorylation. A relatively low effect of both ROCK inhibitors at Thr696 suggests a role for other Ser/Thr kinases at this site. Y-39983 was several-fold more potent when compared with Y-27632 at inhibiting the phosphorylation of MYPT1 at either Thr853 or Thr696 commensurate with its greater potency at inhibiting the activity of human ROCK-I and ROCK-II enzymes.


Subject(s)
Actomyosin/metabolism , Cell-Matrix Junctions/metabolism , Myosin-Light-Chain Phosphatase/metabolism , Phosphoproteins/metabolism , Stress Fibers/drug effects , Trabecular Meshwork , Amides/pharmacology , Aqueous Humor/physiology , Blotting, Western , Cell Line, Transformed , Collagen/analysis , Focal Adhesion Protein-Tyrosine Kinases/analysis , Focal Adhesion Protein-Tyrosine Kinases/biosynthesis , Gels/analysis , Humans , Inhibitory Concentration 50 , Myosin-Light-Chain Phosphatase/antagonists & inhibitors , Paxillin/analysis , Paxillin/biosynthesis , Phosphorylation , Protein Kinase Inhibitors/pharmacology , Pyridines/pharmacology , Reverse Transcriptase Polymerase Chain Reaction , Signal Transduction , Trabecular Meshwork/cytology , Trabecular Meshwork/drug effects , Trabecular Meshwork/metabolism , Vinculin/analysis , Vinculin/biosynthesis
3.
J Ocul Pharmacol Ther ; 20(2): 93-9, 2004 Apr.
Article in English | MEDLINE | ID: mdl-15117564

ABSTRACT

The current study determined the relative affinities and selectivities of numerous beta-adrenoceptor antagonists at the endogenous beta(1)- and beta(2)-adrenoceptors in guinea pig heart and lung, respectively, using [(3)H]-CGP12177. Specific binding of [(3)H]-CGP12177 comprised 80 +/- 0.2% (n = 11) and 94 +/- 0.2% (n = 16) of the total binding in washed heart and lung homogenates, respectively. Concentration-dependent displacement of [(3)H]-CGP12177 binding from beta-adrenoceptors in both preparations was observed with nine different beta-adrenoceptor antagonists. Levobetaxolol, betaxolol, CGP-20712A, levobunolol, and timolol yielded bi-phasic (two-site-fit) competition curves in the heart, while CGP-20712A, ICI-118551 and levobunolol produced bi-phasic curves in the lung preparation. The high-affinity component of [(3)H]-CGP12177 binding in the heart and lung reflected binding to beta(1)-receptors and beta(2)-receptors, respectively. The binding inhibition parameters (IC(50)s) for displacement of [(3)H]-CGP12177 from these predominantly high-affinity sites were: levobetaxolol (24.9 +/- 1.6 nM heart, 4810 +/- 367 nM lung), racemic betaxolol (37.9 +/- 8.7 mM heart; 8840 +/- 424 mM lung), CGP-20712A (4.6 +/- 0.9 nM heart; 171,000 +/- 109,000 nM lung), ICI-118551 (9230 +/- 3240 nM heart; 2.9 +/- 0.6 nM lung), levobunolol (42 +/- 15 nM heart, 0.3 +/- 0.2 nM lung), (l)-timolol (3.1 nM heart, 2.9 +/- 1.5 nM lung), ICI-215001 (5840 +/- 114 nM heart; 26100 +/- 3200 nM lung), BRL-37344 (83,300 +/- 2660 nM heart; 13,200 +/- 1250 lung). These data indicated that while levobetaxolol and betaxolol possessed a 193-233-fold selectivity for beta(1)-receptors, levobunolol exhibited a 140-fold beta(2)-receptor selectivity and (l)-timolol was essentially nonselective.


Subject(s)
Adrenergic beta-Antagonists/pharmacology , Intraocular Pressure/drug effects , Lung/metabolism , Myocardium/metabolism , Receptors, Adrenergic, beta/metabolism , Animals , Betaxolol/pharmacology , Binding, Competitive , Guinea Pigs , Heart/drug effects , In Vitro Techniques , Levobunolol/pharmacology , Lung/drug effects , Timolol/pharmacology
4.
J Pharm Pharmacol ; 56(2): 197-203, 2004 Feb.
Article in English | MEDLINE | ID: mdl-15005878

ABSTRACT

The pharmacological properties of [(3)H]-prostaglandin E(2) ([(3)H]-PGE(2)) binding to washed homogenates of hamster uterus were determined. Scatchard analysis of competition data yielded dissociation constants (K(d)s) of 30.9 +/- 5.6 nM (n = 3) and apparent receptor density (B(max)) of 25.25 +/- 1.89 pmol g(-1) wet weight tissue (74 +/- 8% specific binding). Competition studies yielded the following affinity parameters (K(i)) for various prostanoids: GR63799X = 13 4 nM; PGE(2) = 17 +/- 3 nM; sulprostone = 64 +/- 5 nM; enprostil = 67 +/- 3 nM; misoprostol = 124 +/- 15 nM; cloprostenol = 187 +/- 33 nM; carba-prostacyclin = 260 +/- 167 nM; iloprost = 555 +/- 162 nM; PGF(2 alpha) = 767 +/- 73 nM; PGD(2) > 3560 nM; fluprostenol = 11 790 +/- 2776 nM; RS93520 = 21 558 +/- 14 228 nM. These data closely matched the pharmacological profile of previously described EP(3) receptors such as in bovine corpus luteum (BCLM) and the cloned mammalian EP(3) receptors. The high correlation between the current hamster uterus pharmacology data vs the EP(3) receptor binding in BCLM (r = 0.94; P < 0.0001), vs cloned human EP(3) receptor (r = 0.94, P < 0.0001), vs the cloned mouse EP(3) receptor binding (r = 0.78; P < 0.002), vs cloned rat EP(3) receptor (r = 0.9, P < 0.0004), and vs EP(3) receptor-mediated functional responses (r = 0.72, P < 0.02) substantiated the conclusion that the hamster uterus contains EP(3) receptor binding sites.


Subject(s)
Dinoprost/analogs & derivatives , Epoprostenol/analogs & derivatives , Prostaglandins/pharmacology , Receptors, Prostaglandin E/drug effects , Uterus/cytology , Animals , Binding Sites/drug effects , Biphenyl Compounds/pharmacology , Bridged Bicyclo Compounds, Heterocyclic , Cattle , Cloprostenol/pharmacology , Cricetinae , Dinoprost/pharmacology , Dinoprostone/pharmacology , Enprostil/pharmacology , Epoprostenol/pharmacology , Fatty Acids, Unsaturated , Female , Hydantoins/pharmacology , Hydrazines/pharmacology , Iloprost/pharmacology , Latanoprost , Misoprostol/pharmacology , Prostaglandins E, Synthetic/pharmacology , Prostaglandins F, Synthetic/pharmacology , Receptors, Prostaglandin E/physiology , Receptors, Prostaglandin E, EP3 Subtype , Tritium
5.
Article in English | MEDLINE | ID: mdl-12538087

ABSTRACT

Bimatoprost is the ethyl amide derivative of 17-phenyl-trinor prostaglandin F(2alpha). Here, we show that bimatoprost (K(i)=9250+/-846nM) and bimatoprost free acid (17-phenyl-trinor prostaglandin F(2alpha); K(i)=59+/-6nM) bind to the FP receptor and displace [(3)H]-travoprost acid, a selective FP agonist. Bimatoprost (EC(50)=3070+/-1330nM), Lumigan((R)) (bimatoprost 0.03% ophthalmic solution; EC(50)=1150+/-93nM) and bimatoprost acid (EC(50)=15+/-3nM) mobilized intracellular Ca(2+) ([Ca(2+)](i)) in <5s in HEK-293 cells expressing the cloned human ciliary body FP receptor on a fluorometric imaging plate reader (FLIPR). Furthermore, agonist effects of bimatoprost and bimatoprost acid were blocked by AL-8810 (11beta-fluoro-15-epi-15-indanyl prostaglandin F(2alpha); K(i)=0.7-2.1 MicroM), an FP receptor-selective antagonist. Therefore, the prodrug bimatoprost and its hydrolytic product, bimatoprost free acid, bind to and activate the human ocular FP prostaglandin receptor to mobilize [Ca(2+)](i), thus behaving as FP receptor agonists.


Subject(s)
Calcium/metabolism , Ciliary Body/metabolism , Cloprostenol/analogs & derivatives , Lipids/pharmacology , Receptors, Prostaglandin/agonists , Amides , Bimatoprost , Cloning, Molecular , Cloprostenol/agonists , Cloprostenol/blood , Dose-Response Relationship, Drug , Eye/metabolism , Fluorometry , Humans , Lipid Metabolism , Receptors, Prostaglandin/genetics , Receptors, Prostaglandin/metabolism , Recombinant Fusion Proteins/genetics , Recombinant Fusion Proteins/metabolism , Signal Transduction , Travoprost
6.
J Ocul Pharmacol Ther ; 19(6): 501-15, 2003 Dec.
Article in English | MEDLINE | ID: mdl-14733708

ABSTRACT

Natural prostaglandins (PGs) such as PGD2, PGE2, PGF2(2alpha), and PGI2 exhibited the highest affinity for their respective cognate receptors, but were the least selective agents when tested in receptor binding assays. Travoprost acid ([+]-fluprostenol) was the most FP-receptor-selective compound, exhibiting a high affinity (Ki = 35 +/- 5 nM) for the FP receptor, and minimal affinity for DP (Ki = 52,000 nM), EP1 (Ki = 9540 nM), EP3 (Ki = 3501 nM), EP4 (Ki = 41,000 nM), IP (Ki > 90,000 nM), and TP (Ki = 121,000 nM) receptors. Travoprost acid was the most potent PG analog tested in FP receptor functional phosphoinositide turnover assays in the following cell types: human ciliary muscle (EC50 = 1.4 nM), human trabecular meshwork (EC50 = 3.6 nM), and mouse fibroblasts and rat aortic smooth muscle cells (EC50 = 2.6 nM). Although latanoprost acid exhibited a relatively high affinity for the FP receptor (Ki = 98 nM), it had significant functional activity at FP (EC50 = 32-124 nM) and EP1 (EC50 = 119 nM) receptors. Bimatoprost acid was less selective, exhibiting a relatively high affinity for the FP (Ki = 83 nM), EP1 (Ki = 95 nM), and EP3 (Ki = 387 nM) receptors. Bimatoprost acid exhibited functional activity at the EP1 (EC50 = 2.7 nM) and FP (EC50 = 2.8-3.8 nM in most cells) receptors. Bimatoprost (nonhydrolyzed amide) also behaved as an FP agonist at the cloned human FP receptor (EC50 = 681 nM), in h-TM (EC50 = 3245 nM) and other cell types. Unoprostone and S-1033 bound with low affinity (Ki = 5.9 microM to > 22 microM) to the FP receptor, were not selective, but activated the FP receptor. In conclusion, travoprost acid has the highest affinity, the highest FP-receptor-selectivity, and the highest potency at the FP receptor as compared to the other ocular hypotensive PG analogs known so far, including free acids of latanoprost, bimatoprost, and unoprostone isopropyl ester.


Subject(s)
Binding, Competitive/drug effects , Cloprostenol/analogs & derivatives , Dinoprost/analogs & derivatives , Intraocular Pressure/drug effects , Prostaglandins F, Synthetic/pharmacology , Receptors, Prostaglandin/drug effects , Receptors, Prostaglandin/physiology , Amides , Animals , Aorta/cytology , Aorta/drug effects , Bimatoprost , Binding, Competitive/physiology , Cattle , Cell Line , Ciliary Body/cytology , Ciliary Body/drug effects , Clinical Trials as Topic , Cloprostenol/chemistry , Cloprostenol/metabolism , Cloprostenol/pharmacology , Dinoprost/pharmacology , Drug Evaluation, Preclinical , Fibroblasts/drug effects , Humans , Intraocular Pressure/physiology , Kidney/cytology , Latanoprost , Lipid Metabolism , Lipids/pharmacology , Mice , Prodrugs/chemistry , Prodrugs/metabolism , Prodrugs/pharmacology , Prostaglandins/pharmacology , Prostaglandins F, Synthetic/chemistry , Prostaglandins, Synthetic/chemistry , Prostaglandins, Synthetic/metabolism , Prostaglandins, Synthetic/pharmacology , Radioligand Assay , Rats , Receptors, Prostaglandin/agonists , Receptors, Prostaglandin/classification , Receptors, Prostaglandin E/drug effects , Receptors, Prostaglandin E, EP1 Subtype , Receptors, Prostaglandin E, EP3 Subtype , Second Messenger Systems/drug effects , Second Messenger Systems/physiology , Signal Transduction/drug effects , Signal Transduction/physiology , Stereoisomerism , Trabecular Meshwork/cytology , Trabecular Meshwork/drug effects , Travoprost
7.
J Ocul Pharmacol Ther ; 18(4): 313-24, 2002 Aug.
Article in English | MEDLINE | ID: mdl-12222762

ABSTRACT

We have determined the agonist activity of a number of natural prostaglandins and prostaglandin analogs at the FP prostaglandin receptor cloned from a human ciliary body cDNA library using phosphoinositide (PI) turnover assays. Travoprost acid (EC50 = 3.2 +/- 0.6 nM) was the most potent agonist in these cells followed by bimatoprost free acid (17-phenyl-trinor PGF2alpha; EC50 = 5.8 +/- 2.6 nM), fluprostenol (EC50 = 6.1 +/- 1.5 nM), and latanoprost free acid (PHXA85; EC50 = 54.6 +/- 12.4 nM) which was 17-fold weaker (p < 0.001) than travoprost acid. Unoprostone and S-1033 were significantly (p < 0.001) weaker than travoprost acid. The amide prodrug, bimatoprost (EC50 = 694 +/- 293 nM), activated this FP receptor with an intermediate potency. The isopropyl ester prodrugs, travoprost (EC50 = 42.3 +/- 6.7 nM), latanoprost (EC50 = 126 +/- 347 nM) and unoprostone isopropyl ester (EC50 = 9,100 +/- 2,870 nM), also exhibited FP agonist activity. However, other compounds such as PGI2, bradykinin, histamine, and serotonin were inactive. The agonist activities of bimatoprost, unoprostone (UF-021), fluprostenol and acids of travoprost and latanoprost were antagonized by AL-8810 (11beta-fluoro- 15-epi-15-indanyl-PGF2alpha), an FP-receptor-selective antagonist (Ki = 1.0 - 2.1 microM; n = 3). These studies have demonstrated, for the first time, agonist activities of the currently known and marketed ocular hypotensive prostaglandin analogs at the cloned human ciliary body FP prostaglandin receptor.


Subject(s)
Ciliary Body/drug effects , Cloprostenol/analogs & derivatives , Dinoprost/analogs & derivatives , Prostaglandins/pharmacology , Receptors, Prostaglandin/agonists , Amides , Bimatoprost , Cells, Cultured , Ciliary Body/cytology , Ciliary Body/metabolism , Cloning, Molecular , Cloprostenol/pharmacology , Dinoprost/pharmacology , Dose-Response Relationship, Drug , Humans , Latanoprost , Lipids/pharmacology , Prostaglandins F, Synthetic/pharmacology , Receptors, Prostaglandin/genetics , Receptors, Prostaglandin/metabolism , Travoprost
8.
J Ocul Pharmacol Ther ; 18(2): 141-62, 2002 Apr.
Article in English | MEDLINE | ID: mdl-12002668

ABSTRACT

Immortalized human non-pigmented ciliary epithelial (NPE) cells (ODM-2) were shown to express the mRNA for the prostanoid TPalpha but not the TPbeta receptor using reverse transcription-polymerase chain reaction (RT-PCR). These TPalpha receptors were coupled to phospholipase C (PLC) and, thus, promoted phosphoinositide (PI) turnover. TP receptor agonists yielded the following potencies (EC50S) in the PI turnover assays: I-BOP = 8.2 +/- 1.1 nM; carbocyclic TA2 = 87.5 +/- 25.3 nM; U-44069 = 1.16 +/- 0.32 microM; U-46619 = 1.2 +/- 0.2 microM (n = 4-17). Agonists selective for other prostanoid receptor subtypes (e.g., fluprostenol and sulprostone) were inactive. The agonist effects of U-44619 and I-BOP were potently blocked, in an apparent non-competitive manner (ki = 53.9 +/- 12 nM; pA2s = 7.6-7.8; pKbs = 7.38), by the TP receptor-selective antagonist, SQ29,548, but were unaffected by other prostanoid receptor antagonists (e.g., AH6809, AL-8810). The PLC inhibitor (U73122) inhibited U-46619-induced PI turnover (IC50 = 4.3 +/- 0.6 microM). The functional potencies of the compounds stimulating or inhibiting the TP receptor-mediated PI turnover in the NPE cells correlated well with the TP receptor binding affinities of these compounds at human platelet TP receptors (r = 0.98). These studies have shown the presence of the mRNA for and the expression of functional TPalpha receptors coupled to PLC in human NPE cells. The TPalpha receptors on NPE cells may be responsible for inhibiting aqueous humor production and may help explain the intraocular pressure-lowering effects of certain TP agonists.


Subject(s)
Ciliary Body/metabolism , Receptors, Thromboxane/metabolism , Alternative Splicing , Cell Line, Transformed , Ciliary Body/cytology , Epithelial Cells/metabolism , Humans , Phosphatidylinositols/metabolism , RNA, Messenger/metabolism , Receptors, Prostaglandin E/genetics , Receptors, Prostaglandin E, EP2 Subtype , Receptors, Thromboxane/genetics , Reverse Transcriptase Polymerase Chain Reaction
9.
Eur J Pharmacol ; 432(2-3): 211-3, 2001 Dec 07.
Article in English | MEDLINE | ID: mdl-11740958

ABSTRACT

Bimatoprost (17-phenyl-prostaglandin F(2alpha) ethyl amide) has been reported not to exert its actions via prostaglandin receptors. Here, bimatoprost displaced [3H]prostaglandin F(2alpha) from FP receptors (K(i)=6310+/-1650 nM). Bimatoprost rapidly mobilized intracellular Ca(2+) ([Ca(2+)](i)) via cloned human FP receptors expressed in human embryonic kidney cells (EC(50)=2940+/-1663 nM) and via native FP receptors in 3T3 mouse fibroblasts (EC(50)=2200+/-670 nM). Furthermore, AL-8810 ((5Z, 13E)-(9S,11S,15R)-9,15-dihydroxy-11-fluoro-15-(2-indanyl)-16,17,18,19,20-pentanor-5,13-prostadienoic acid), an FP receptor antagonist, blocked the bimatoprost-induced [Ca(2+)](i) mobilization.


Subject(s)
Dinoprost/analogs & derivatives , Lipid Metabolism , Receptors, Prostaglandin/metabolism , 3T3 Cells , Amides , Animals , Bimatoprost , Binding, Competitive/drug effects , Calcium/metabolism , Cell Line , Cloprostenol/analogs & derivatives , Dinoprost/metabolism , Dinoprost/pharmacology , Dose-Response Relationship, Drug , Humans , Lipids/pharmacology , Mice , Receptors, Prostaglandin/agonists , Receptors, Prostaglandin/antagonists & inhibitors , Tritium
10.
J Ocul Pharmacol Ther ; 17(4): 305-17, 2001 Aug.
Article in English | MEDLINE | ID: mdl-11572462

ABSTRACT

The pharmacological characteristics of levobetaxolol, a single active isomer of betaxolol, were determined and compared with activities of other beta-adrenoceptor antagonists. Levobetaxolol (43-fold beta1-selective) exhibited a higher affinity at cloned human beta1 (Ki = 0.76 nM) than at beta2 (Ki = 32.6 nM) receptors, while dextrobetaxolol was much weaker at both receptors. Levobetaxolol potently antagonized functional activities at cloned human beta1 and beta2 receptors, and also at guinea pig atrial beta1, tracheal beta2 and rat colonic beta3 receptors (IC50s = 33.2 nM, 2970 nM and 709 nM, respectively). Thus, levobetaxolol was 89-times beta1-selective (vs beta2). Levobetaxolol (Ki = 16.4 nM) was more potent than dextrobetaxolol (Ki = 2.97 microM) at inhibiting isoproterenol-induced cAMP production in human non-pigmented ciliary epithelial cells. Levobunolol and (l)-timolol had high affinities at beta1 and beta2 receptors but were considerably less beta1-selective than levobetaxolol. Levo-, dextro- and racemic-betaxolol exhibited little or no affinity, except at sigma sites and Ca2+-channels (IC50s > 1 microM), at 89 other receptor/ligand binding sites. Levobetaxolol exhibited a micromolar affinity for L-type Ca2+-channels. In conscious ocular hypertensive cynomolgus monkeys, levobetaxolol was more potent than dextrobetaxolol, reducing intraocular pressure by 25.9+/-3.2% at a dose of 150 microg/eye (n = 15-30). Quantitative [3H]-levobetaxolol autoradiography revealed high levels of binding to human ciliary processes, iris, choroid/retina, and ciliary muscles. In conclusion, levobetaxolol is a potent, high affinity and beta1-selective IOP-lowering beta-adrenoceptor antagonist.


Subject(s)
Adrenergic beta-Antagonists/pharmacology , Betaxolol/pharmacology , Ciliary Body/drug effects , Intraocular Pressure/drug effects , Adrenergic beta-Agonists/pharmacology , Animals , Cell Line , Ciliary Body/cytology , Ciliary Body/metabolism , Cyclic AMP/biosynthesis , Drug Evaluation, Preclinical , Epithelial Cells/drug effects , Female , Guinea Pigs , Humans , Isomerism , Isoproterenol/antagonists & inhibitors , Isoproterenol/pharmacology , Macaca fascicularis , Male , Pigment Epithelium of Eye/drug effects , Rats , Receptors, Adrenergic, beta/metabolism
11.
J Med Chem ; 44(20): 3283-91, 2001 Sep 27.
Article in English | MEDLINE | ID: mdl-11563927

ABSTRACT

Certain phenylethylamines, such as 1-(4-bromo-2,5-dimethoxyphenyl)-2-aminopropane (DOB; 1a), are high-affinity 5-HT(2) agonists. Previous structure-affinity studies have concluded that both the 2,5-dimethoxy substitution pattern and the nature of substituents at the 4-position are important determinants of high affinity. We recently demonstrated that replacement of the bromo group of DOB with a 3-(phenyl)propyl substituent results in retention of affinity and that, counter to established structure-affinity relationships, the 2,5-dimethoxy substitution pattern is no longer a requirement for the binding. The present investigation extends these findings by examining a series of analogues, 3, lacking a 5-methoxy group. It was additionally found that shifting the phenylalkyl substituent from the 4- to the 5-position (e.g., 4i) also results in retention of affinity. For example, 1-(2-methoxy-5-(3-phenylpropyl)-2-aminopropane (6; the alpha-methyl derivative of 4i) binds at 5-HT(2A) receptors with high affinity (K(i) = 13 nM) and possesses 5-HT(2A) antagonist character. Thus, not only is the 2,5-dimethoxy substitution pattern not a requirement for the binding of certain phenylethylamines at 5-HT(2A) receptors, the presence of a 4-position substituent (previously thought to serve as a modulator of affinity of DOB-like agents) is also not required. Striking differences in the 5-HT(2A) binding requirements of the present compounds as compared to DOB-like agents suggest multiple substituent-dependent modes of binding.


Subject(s)
Propylamines/chemical synthesis , Receptors, Serotonin/metabolism , Serotonin Antagonists/chemical synthesis , 3T3 Cells , Animals , Cells, Cultured , Hydrolysis , Inositol Phosphates/metabolism , Mice , Models, Molecular , Muscle, Smooth, Vascular/cytology , Propylamines/chemistry , Propylamines/metabolism , Propylamines/pharmacology , Radioligand Assay , Rats , Receptor, Serotonin, 5-HT2A , Receptor, Serotonin, 5-HT2C , Serotonin Antagonists/chemistry , Serotonin Antagonists/metabolism , Serotonin Antagonists/pharmacology , Structure-Activity Relationship
12.
Exp Eye Res ; 73(1): 59-67, 2001 Jul.
Article in English | MEDLINE | ID: mdl-11428863

ABSTRACT

In the present study, we investigated the pharmacological characteristics of electrically stimulated [(3)H]-serotonin release from mammalian iris-ciliary bodies. Isolated bovine and human iris-ciliary bodies were loaded with [(3)H]-serotonin, superfused with Krebs buffer solution and then stimulated with trains of 300 direct current (d.c.) pulses to initiate the release of the transmitter. The modification of this [(3)H]-serotonin release process by various serotonergic agonists and antagonists was studied in order to define the pharmacology of serotonin receptor(s) present in the iris-ciliary body. In bovine iris-ciliary body, electrically-evoked [(3)H]-serotonin release was calcium-dependent, tetrodotoxin-sensitive and was enhanced by serotonin (EC(50) = 200 n M) and 5-carboxmidotryptamine (EC(50) = 4 n M). The rank order of potency of agonists in enhancing field-stimulated [(3)H]-serotonin release was: 5-carboamidotryptamine > m-chlorophenylbiguanide > 2-methyl-5-hydroxytryptamine = 5-methoxy-dimethyltryptamine > serotonin > 5-methoxy-tryptamine > L-694,247 = alpha-methyl-5-hydroxytryptamine > CGS 12066A = 8-hydroxy-2-(di- n -propylamino)tetraline. Serotonin and m-chlorophenylbiguanide also enhanced electrically-evoked [(3)H]-serotonin release from human iris-ciliary bodies with EC(50)s of 3 microM and 30 n M, respectively. The pharmacological profile displayed by serotonin receptor agonists was supported by the potent antagonism of the serotonin-induced enhancement of [(3)H]-serotonin release by 5HT(7)receptor antagonists SB-258718 (IC(50) = 18.6 +/- 1.2 nM; n = 4) and mesulergine (IC(50) = 0.26 +/- 0.05 nM; n = 4). However, antagonists at 5HT(6)and 5HT(3)receptors exhibited a relatively weak blockade of serotonin induced enhancement of field-stimulated [(3)H]-serotonin release. These studies have shown the presence of functionally active prejunctional 5HT(7)autoreceptors regulating the release of [(3)H]-serotonin from bovine iris-ciliary bodies. Excitatory prejunctional 5-HT autoreceptors also exist in human iris-ciliary bodies. It is possible that these serotonin autoreceptors may have relevance to the regulation of aqueous humor dynamics in the anterior uvea.


Subject(s)
Ciliary Body/metabolism , Iris/metabolism , Receptors, Serotonin/metabolism , Serotonin/metabolism , Tritium/metabolism , Adult , Aged , Analysis of Variance , Animals , Cattle , Ciliary Body/drug effects , Electric Stimulation , Humans , Iris/drug effects , Middle Aged , Receptors, Serotonin/drug effects , Serotonin Antagonists/pharmacology , Serotonin Receptor Agonists/pharmacology
13.
J Ocul Pharmacol Ther ; 17(1): 35-46, 2001 Feb.
Article in English | MEDLINE | ID: mdl-11322636

ABSTRACT

The aim of these studies was to characterize the molecular pharmacology of the prostanoid receptors positively coupled to stimulation of adenylyl cyclase activity in immortalized human trabecular meshwork (TM-3) cells and to compare these results with that of the receptors in immortalized human nonpigmented epithelial (NPE) cells. In general, the TM-3 and NPE cells showed a similar profile with respect to their responses to various prostaglandin (PG) receptor agonists. The rank order of potency (EC50; means +/- SEM) for these compounds in the TM-3 cells was: PGE2 (124 +/- 21 nM) > 13,14-dihydro-PGE1 (430 +/- 110 nM) = PGE1 (522 +/- 345 nM) > 11-deoxy-PGE1 (1063 +/- 118 nM) = 16,16-dimethyl-PGE2 (1776 +/- 460 nM) = butaprost (1920 +/- 527 nM) >> PGD2 = PGI2 = PGF2alpha (n = 3 - 12). While the agonist profile indicated the presence of EP2 receptors, the effects of the EP4 receptor antagonists suggested the additional expression of EP4 receptors in both of these cells. Thus, the EP4 receptor antagonist, AH23848B, at a concentration of 30 microM, caused a dextral shift in the PGE2 concentration-response curves in both TM-3 and NPE cells coupled with a 20-28% decrease in the maximal response of PGE2, indicating apparent noncompetitive antagonism profiles. The antagonist potency of AH23848B in these cells was: Kb = 38.4 +/- 14.8 microM and 23.5 +/- 4.5 microM; -log Kb = 4.7. The other EP4 receptor antagonist, AH22921 (-log Kb = 4.1 - 4.7), was weaker than AH23848B. Taken together, these pharmacological studies have shown than TM-3 and NPE cells apparently contain functional EP2 and EP4 prostanoid receptors positively coupled to adenylyl cyclase.


Subject(s)
Ciliary Body/metabolism , Epithelial Cells/metabolism , Receptors, Prostaglandin E/metabolism , Trabecular Meshwork/metabolism , Adenylyl Cyclases/metabolism , Cells, Cultured , Ciliary Body/cytology , Ciliary Body/drug effects , Epithelial Cells/cytology , Epithelial Cells/drug effects , Humans , Pigment Epithelium of Eye/cytology , Pigment Epithelium of Eye/drug effects , Pigment Epithelium of Eye/metabolism , Prostaglandins/pharmacology , Receptors, Prostaglandin E/agonists , Receptors, Prostaglandin E/antagonists & inhibitors , Receptors, Prostaglandin E, EP2 Subtype , Receptors, Prostaglandin E, EP4 Subtype , Trabecular Meshwork/cytology , Trabecular Meshwork/drug effects
14.
Curr Eye Res ; 23(5): 386-92, 2001 Nov.
Article in English | MEDLINE | ID: mdl-11910529

ABSTRACT

PURPOSE: The aim of the present study was two-fold: (a) to examine the effect of hypoxia on [(3)H]D-aspartate release from isolated bovine and human retinae, and (b) to investigate the regulation of hypoxia-induced neurotransmitter release by glutamate receptor agonists and antagonists. METHODS: Isolated neural retinae were incubated in oxygenated Krebs buffer solution containing [(3)H]D-aspartate and then prepared for studies of neurotransmitter release using the superfusion method. Release of [(3)H]D-aspartate was evoked by K(+) (50 mM) applied at 90 minutes (S(1)) and hypoxia (induced by exposure of tissues to solutions pregassed with 95%N(2): 5% CO(2) for 60 minutes) at 108 minutes (S(2)) after onset of superfusion. RESULTS: Under hypoxic conditions, pO(2) in normal Krebs buffer solution was reduced from 14.53 +/- 0.26 ppm (n = 6) to 0.54 +/- 0.04 ppm (n = 9) after one hour of gassing with 95% N(2): 5% CO( 2). Exposure to hypoxia elicited an overflow of [(3)H]D-aspartate yielding S(2)/S(1) ratios of 0.62 +/- 0.06 (n = 12) and 0.54 +/- 0.03 (n = 8) in bovine and human tissues respectively. In isolated bovine retinae, L- and N-calcium-channel antagonists diltiazem, nitrendipine, verapamil and omega-conotoxin significantly (p < 0.01 or higher) attenuated hypoxia-induced [(3)H]D-aspartate release. L-glutamate (30 microM) significantly (p < 0.001) potentiated hypoxia-induced [(3)H]D-aspartate release whereas kainate (30 microM) inhibited this response. NMDA (in concentrations up to 1 mM) had no effect on hypoxia-induced [(3)H]D-aspartate release. Antagonists of glutamate receptors and the polyamine site on the NMDA receptor inhibited hypoxia-induced release of [(3)H]D-aspartate in bovine retina with the following rank order of activity: ifenprodil congruent with MCPG > L-AP3 > MK-801. At an equimolar concentration (10 microM), L-AP3 but not ifenprodil, MCPG, MK 801 or arcaine, caused a significant (p < 0.001) inhibition of hypoxia-induced [(3)H]D-aspartate release from human retinae. CONCLUSIONS: Hypoxia can induce the release of [( 3)H]D-aspartate from isolated bovine retinae by a calcium-dependent process. Hypoxia-induced [(3)H]D-aspartate release from isolated bovine retinae can be regulated by glutamate receptor agonists/antagonists and blockers of polyamine site on the NMDA receptor.


Subject(s)
Calcium Channel Blockers/pharmacology , D-Aspartic Acid/metabolism , Excitatory Amino Acid Agonists/pharmacology , Excitatory Amino Acid Antagonists/pharmacology , Hypoxia/metabolism , Receptors, Neurotransmitter/metabolism , Retina/metabolism , Adult , Aged , Animals , Cattle , Humans , Middle Aged , Potassium/pharmacology , Retina/drug effects
15.
Article in English | MEDLINE | ID: mdl-11993717

ABSTRACT

The objective of these studies was to characterize the effects of a broad range of prostanoid agonists upon the stimulation of cAMP production in National Cancer Bank (NCB-20; mouse neuroblastoma/hamster brain hybridoma) cells. The pharmacology of these functional responses in NCB-20 cells was compared with that of the classic endogenous IP receptor present on human platelets using [3H]-iloprost binding techniques. In both assay systems, agonists from the IP prostanoid class exhibited the highest affinities and functional potencies. Specific prostanoids exhibited the following rank order of potency (EC50 +/- SEM) in stimulating cAMP production in the NCB-20 cells: carbaprostacyclin (4.3 +/- 0.9 nM) = PGI2 (6.6 +/-1.5 nM) > iloprost (75+/-13 nM) > 11-deoxy PGE, (378+/-138 nM) > misoprostol (1,243+/-48) > PGE2 (3020+/-700 nM) > ZK-118182 (7265+/-455 nM). Iloprost wasthe most potent compound in the human platelet binding assay while prostanoidsfromthe DPand EP receptor classes showed modest affinity. These studies provide functional and binding information for a broad range of both natural and synthetic prostanoid receptor ligands at the endogenous IP receptor in two different cell types.


Subject(s)
Alprostadil/analogs & derivatives , Blood Platelets/metabolism , Dinoprost/analogs & derivatives , Receptors, Prostaglandin/metabolism , Alprostadil/metabolism , Alprostadil/pharmacology , Animals , Cyclic AMP/metabolism , Dinoprost/metabolism , Dinoprost/pharmacology , Dinoprostone/metabolism , Dinoprostone/pharmacology , Humans , Iloprost/metabolism , Iloprost/pharmacology , Mice , Misoprostol/metabolism , Misoprostol/pharmacology , Neuroblastoma/metabolism , Radioimmunoassay , Receptors, Epoprostenol , Receptors, Prostaglandin/agonists , Receptors, Prostaglandin/drug effects , Tumor Cells, Cultured
16.
J Ocul Pharmacol Ther ; 17(5): 421-32, 2001 Oct.
Article in English | MEDLINE | ID: mdl-11765147

ABSTRACT

Travoprost is the isopropyl ester prodrug of a high affinity, selective FP prostaglandin full receptor agonist. In contrast to travoprost acid's high affinity and efficacy at the FP receptor, there is only sub-micromolar affinity for the DP, EP1, EP3, EP4, IP, and TP receptors. Travoprost produced a lower incidence of ocular irritation than PGF20 isopropyl ester at a dose of 1 microg in the New Zealand albino (NZA) rabbit. Topical ocular application of travoprost produced a marked miotic effect in cats following doses of 0.01, 0.03 and 0.1 microg. In the ocular hypertensive monkey, b.i.d. application of 0.1 and 0.3 microg of travoprost afforded peak reduction in intraocular pressure (IOP) of 22.7% and 28.6%, respectively. Topical application of travoprost was well tolerated in rabbits, cats and monkeys, causing no ocular irritation or discomfort at doses up to 1 microg. Travoprost is a promising ocular hypotensive prostaglandin FP derivative that has the ocular hypotensive efficacy of PGF2alpha isopropyl ester but with less severe ocular side effects.


Subject(s)
Antihypertensive Agents/pharmacology , Cloprostenol/pharmacology , Receptors, Prostaglandin/agonists , Adenylyl Cyclases/metabolism , Administration, Topical , Animals , Cats , Cattle , Cloprostenol/analogs & derivatives , Corpus Luteum/metabolism , Dinoprost/metabolism , Dose-Response Relationship, Drug , Drug Evaluation, Preclinical , Female , Fibroblasts/drug effects , Humans , Intraocular Pressure/drug effects , Macaca , Mice , Ocular Hypertension/drug therapy , Ophthalmic Solutions , Phosphatidylinositols/metabolism , Rabbits , Trabecular Meshwork/drug effects , Travoprost
18.
Br J Pharmacol ; 131(6): 1025-38, 2000 Nov.
Article in English | MEDLINE | ID: mdl-11082108

ABSTRACT

1. A potent and highly selective DP prostanoid receptor antagonist radioligand, [(3)H]-cyclohexyl-N-BWA868C (3-benzyl-5-(6-carboxyhexyl)-1-(2-cyclohexyl-2-hydroxyethyl-amino) hydantoin, ([(3)H]-BWA868C)), has been generated for receptor binding and autoradiographic studies. 2. Specific [(3)H]-BWA868C binding to human platelet membranes achieved equilibrium within 60 min at 23 degrees C and constituted up to 95% of the total binding. The association (K(+1)) and dissociation (K(-1)) rate constants of binding were 0.758+/-0.064 min(-1), mmol and 0.0042+/-0.0002 min(-1), respectively, yielding dissociation constants (K(D)s) of 5.66+/-0. 44 nM (n=4). 3. Specific [(3)H]-BWA868C bound to DP receptors with a high affinity (K(D)=1.45+/-0.01 nM, n=3) and to a finite, saturable number of binding sites (B(max)=21.1+/-0.6 nmol g(-1) wet weight). 4. DP receptor class prostanoids (e.g. ZK118182, BW245C, BWA868C, PGD(2)) exhibited high (nanomolar) affinities for [(3)H]-BWA868C binding, while prostanoids selective for EP, FP, IP and TP receptors showed a low (micromolar) affinity. 5. Specific DP receptor binding sites were autoradiographically localized on the ciliary epithelium/process, longitudinal and circular ciliary muscles, retinal choroid and iris in human eye sections using [(3)H]-BWA868C. While [(3)H]-PGD(2) yielded similar quantitative distribution of DP receptors as [(3)H]-BWA868C, the level of non-specific binding observed with [(3)H]-PGD(2) was significantly greater than that observed with [(3)H]-BWA868C. 6. It is concluded that [(3)H]-BWA868C is a high-affinity and very specific DP receptor radioligand capable of selectively labelling the DP receptor. [(3)H]-BWA868C may prove useful for future homogenate-based and autoradiographic studies on the DP receptor.


Subject(s)
Blood Platelets/metabolism , Eye/metabolism , Hydantoins/metabolism , Platelet Aggregation Inhibitors/metabolism , Prostaglandin D2/metabolism , Receptors, Immunologic , Receptors, Prostaglandin/metabolism , Autoradiography , Cell Membrane/metabolism , Humans
19.
J Med Chem ; 43(18): 3400-7, 2000 Sep 07.
Article in English | MEDLINE | ID: mdl-10978187

ABSTRACT

The racemic cyclohexane-for-cyclopentane ring substitution analogue of the potent prostaglandin FP agonist cloprostenol (7) was synthesized from cyclohexenediol 11 in 21 steps and 0.07% yield. In a prostaglandin FP receptor-linked second-messenger assay, racemic analogue 7 exhibited an EC(50) value of 319 nM (72% response relative to cloprostenol); the corresponding values for PGF(2)(alpha) and cloprostenol were 23 nM (91% relative response) and 1 nM (defined as 100% response), respectively. Key features of the synthesis were the selective manipulation of four hydroxyl groups to direct independent elaboration of the alpha and omega chains and a new method for synthesis of aryloxy-terminated omega chains involving Horner-Emmons elongation of an aldehyde to a methyl enone, regioselective bromination adjacent to the carbonyl, and phenoxide displacement of bromide.


Subject(s)
Cloprostenol/analogs & derivatives , Cloprostenol/chemical synthesis , Receptors, Prostaglandin/agonists , 3T3 Cells , Animals , Cloprostenol/chemistry , Cloprostenol/pharmacology , Corpus Luteum/metabolism , Female , In Vitro Techniques , Inositol Phosphates/biosynthesis , Ligands , Mice , Receptors, Prostaglandin/metabolism , Stereoisomerism , Structure-Activity Relationship
20.
Br J Pharmacol ; 130(8): 1919-26, 2000 Aug.
Article in English | MEDLINE | ID: mdl-10952683

ABSTRACT

Prostaglandin (PG) E(2) (PGE(2)) is a potent prostanoid derived from arachidonic which can interact with EP(1), EP(2), EP(3) and EP(4) prostanoid receptor subtypes. Recombinant human EP(4) receptors expressed in human embryonic kidney (HEK-293) cells were evaluated for their binding characteristics using [(3)H]-PGE(2) and a broad panel of natural and synthetic prostanoids in order to define their pharmacological properties. [(3)H]-PGE(2) binding was optimal in 2-[N-Morpholino]ethanesulphonic acid (MES) buffer (pH 6.0) yielding 98+/-0.7% specific binding. The receptor displayed high affinity (K(d)=0.72+/-0.12 nM; n=3) for [(3)H]-PGE(2) and interacted with a saturable number of binding sites (B(max)=6.21+/-0.84 pmol mg(-1) protein). In competition studies, PGE(2) (K(i)=0.75+/-0.03 nM; n=12) and PGE(1) (K(i)=1.45+/-0.24 nM; n=3) displayed high affinities, as did two derivatives of PGE(1), namely 11-deoxy-PGE(1) (K(i)=1.36+/-0.34 nM) and 13,14-dihydro-PGE(1) (K(i)=3.07+/-0.29 nM). Interestingly, synthetic DP receptor-specific agonists such as BW245C (K(i)=64.7+/-1.0 nM; n=3) and ZK118182 (K(i)=425+/-42 nM; n=4), and the purported EP(3) receptor-specific ligand enprostil (K(i)=43.1+/-4.4 nM), also displayed high affinity for the EP(4) receptor. Two known EP(4) receptor antagonists were weak inhibitors of [(3)H]-PGE(2) binding akin to their known functional potencies, thus: AH23848 (K(i)=2690+/-232 nM); AH22921 (K(i)=31,800+/-4090 nM). These studies have provided a detailed pharmacological characterization of the recombinant human EP(4) receptor expressed in HEK-293 cells.


Subject(s)
Dinoprostone/metabolism , Receptors, Prostaglandin E/metabolism , Binding, Competitive/drug effects , Cell Line , Cell Membrane/drug effects , Cell Membrane/metabolism , DNA, Recombinant , Dinoprostone/pharmacology , Dose-Response Relationship, Drug , Humans , Ligands , Prostaglandins/metabolism , Prostaglandins/pharmacology , Radioligand Assay , Receptors, Prostaglandin E/genetics , Receptors, Prostaglandin E, EP4 Subtype , Tritium
SELECTION OF CITATIONS
SEARCH DETAIL
...